The Role of SF2 in Prostate Cancer Progression
Abstract
Background: Prostate cancer (PCa), a leading cause of male mortality, development and progression is dependent upon androgen and androgen receptor (AR) signaling. Current therapies target androgen production and/or AR signaling. Evidence suggests that AR in some tumors may escape therapy through mechanisms that likely involve splicing. Purpose: To better understand splicing during PCa development or progression. Scope: Observations suggest that the splicing factor (SF2) may contribute to PCa. Findings: i) IHC analysis, suggests SF2 is elevated in human PCa specimens, ii) PCa-derived cell model systems with altered levels of SF2 that mimic human disease, suggests proliferative phenotype, iii) Knockdown of SF2, suggests PCa-specific splicing. Recent progress: i) Immunoblot analysis of SF2 in primary PCa tissue lysates validated IHC findings, ii) Knockdown of SF2 promotes G2/M arrest, iii) Tissue recombination assays yielded no identifiable glandular structures, iv) An ex vivo primary PCa culture system was developed to evaluate future splicing and therapeutic potential.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2013
- Accession Number
- ADA580377
Entities
People
- Clay Comstock
Organizations
- Thomas Jefferson University